Blog
RSS FeedPosted by Michael Wonder on 24 Oct 2019
Knight Therapeutics and SIFI announce approval of Netildex in Canada
23 October 2019 - Knight Therapeutics and SIFI today announced that Health Canada has approved Netildex for the treatment of inflammatory ...
Posted by Michael Wonder on 21 Oct 2019
Bausch Health announces updated Health Canada safety information for Elidel
17 October 2019 - Topical atopic dermatitis treatment Elidel now available for children three months and over. ...
Posted by Michael Wonder on 19 Oct 2019
Cipher Pharmaceuticals receives Health Canada approval for Trulance (plecanatide)
18 October 2019 - Cipher Pharmaceuticals today announced it has received Health Canada approval, on 10 October 2019, for Trulance (plecanatide), ...
Posted by Michael Wonder on 16 Oct 2019
Health Canada approves Ipsen's Cabometyx (cabozantinib) for the first-line treatment of adults with advanced renal cell carcinoma
15 October 2019 - Cabometyx demonstrated a statistically significant, 52% reduction in the risk of progression or death compared with sunitinib, ...
Posted by Michael Wonder on 10 Oct 2019
Two new options for self-administration of Nucala now approved in Canada, making it the first anti-IL5 biologic to offer patients with severe eosinophilic asthma a choice of how and where to receive treatment
9 October 2019 - Nucala (mepolizumab) has been approved in Canada in two new formats – a pre-filled auto-injector and ...
Posted by Michael Wonder on 09 Oct 2019
Health Canada approves Evenity for the treatment of osteoporosis in post-menopausal women at high risk for fracture
8 October 2019 - Today Amgen Canada announced that Evenity (romosozumab) is now available in Canada for the treatment of osteoporosis ...
Posted by Michael Wonder on 09 Oct 2019
Health Canada approves Calquence (acalabrutinib) for adult patients with previously-treated mantle cell lymphoma
8 October 2019 - Approval of the highly selective Bruton's tyrosine kinase inhibitor in mantle cell lymphoma marks AstraZeneca's entry ...
Posted by Michael Wonder on 01 Oct 2019
Symbicort Turbuhaler now approved by Health Canada for use in mild persistent, moderate, or severe asthma
30 September 2019 - AstraZeneca Canada announced today that Health Canada has approved the expanded use of Symbicort Turbuhaler (budesonide/formoterol) ...
Posted by Michael Wonder on 30 Sep 2019
Health Canada approves Dupixent as the first biologic for the treatment of adolescents with moderate-to-severe atopic dermatitis
27 September 2019 - Dupixent can significantly reduce the constant itch and improve the skin's overall condition. ...
Posted by Michael Wonder on 28 Sep 2019
Health Canada approves Tecentriq in combination with chemotherapy (nab-paclitaxel) as first immunotherapy treatment for aggressive form of breast cancer
27 September 2019 - New approval provides patients with PD-L1 positive, metastatic triple-negative breast cancer with an additional treatment option that ...
Posted by Michael Wonder on 11 Sep 2019
Canada OKs Celltrion's biosimilar
10 September 2019 - Celltrion said that Health Canada has given the go-ahead for Herzuma (trastuzumab), an anticancer antibody biosimilar, ...
Posted by Michael Wonder on 14 Aug 2019
Health Canada approves Tecentriq (atezolizumab), first new treatment in 20 years for aggressive form of lung cancer
13 August 2019 - Data show Tecentriq in combination with carboplatin and etoposide helped patients with extensive-stage small cell lung ...
Posted by Michael Wonder on 31 Jul 2019
Health Canada approves Vitrakvi (larotrectinib), the first tumour agnostic cancer treatment for advanced solid tumours harbouring an NTRK gene fusion
30 July 2019 - Bayer announced today that there is now a treatment in Canada for tyrosine receptor kinase fusion ...
Posted by Michael Wonder on 24 Jul 2019
Alnylam launches Onpattro (patisiran) for the treatment of polyneuropathy in hATTR amyloidosis, the first-ever RNAi therapeutic approved in Canada
23 July 2019 - Onpattro is the only treatment that demonstrated improvement, relative to baseline, in both polyneuropathy and quality ...
Posted by Michael Wonder on 17 Jul 2019
Knight Therapeutics announces Health Canada has approved Nerlynx for early-stage breast cancer
16 July 2019 - Knight Therapeutics announced today that Health Canada has approved Nerlynx (neratinib) for the extended adjuvant treatment of ...